Albutrepenonacog Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Albutrepenonacog alfa: From Hemophilia B to Pseudo-von Willebrand Disease
One-Sentence Summary
Albutrepenonacog alfa (rIX-FP) is a recombinant Factor IX albumin fusion protein designed to provide long-acting coagulation factor replacement for Hemophilia B (congenital Factor IX deficiency). The TxGNN model predicts it may be effective for Pseudo-von Willebrand Disease, however there are currently 0 clinical trials and 0 publications supporting this direction, and the mechanistic rationale is assessed as extremely weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemophilia B (congenital Factor IX deficiency) |
| Predicted New Indication | Pseudo-von Willebrand Disease |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacological knowledge, Albutrepenonacog alfa is a recombinant human Factor IX fused to human serum albumin (rIX-FP), engineered to extend the circulating half-life of Factor IX to approximately 104 hours—roughly 5-fold longer than standard Factor IX concentrates. This enables once-weekly or less frequent prophylactic dosing in patients with Hemophilia B, where Factor IX activity is congenitally absent or severely reduced, impairing the intrinsic coagulation pathway (Xase complex: FIXa + FVIIIa → FXa).
Pseudo-von Willebrand disease (platelet-type vWD) is caused by a gain-of-function mutation in GPIbα on the platelet surface, which creates abnormally high affinity for von Willebrand Factor (vWF). This leads to spontaneous platelet-vWF binding, resulting in platelet aggregation and selective consumption of high-molecular-weight vWF multimers. The pathological mechanism operates entirely within the primary hemostasis axis (platelet/vWF interaction), and is structurally and functionally distinct from the coagulation cascade where Factor IX functions.
Mechanistic relevance is extremely low: supplementing Factor IX cannot correct GPIbα gain-of-function abnormalities, replace consumed vWF multimers, or prevent spontaneous platelet aggregation. The TxGNN model's high prediction score (99.94%) most likely reflects shared rare bleeding disorder ontology in the knowledge graph rather than true mechanistic or therapeutic overlap. Among all 10 predicted indications in this analysis, only acquired coagulation factor deficiency (Rank 7) carries a meaningful mechanistic link to Factor IX replacement therapy, as it may encompass acquired Factor IX deficiency (e.g., in systemic amyloidosis).
Clinical Trial Evidence
Currently no related clinical trials registered for pseudo-von Willebrand disease.
Literature Evidence
Currently no related literature available for pseudo-von Willebrand disease.
Singapore Market Information
Albutrepenonacog alfa is currently not registered in Singapore. No HSA-authorised products containing this active substance have been identified. This drug is therefore not commercially available through standard regulatory channels in Singapore.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score (99.94%), pseudo-von Willebrand disease involves a primary hemostasis defect in GPIbα/vWF interaction that is mechanistically orthogonal to Factor IX replacement therapy; there is no clinical, preclinical, or biological rationale supporting this repurposing direction, and no supporting evidence exists.
To proceed, the following is needed:
- Obtain and review the full prescribing information (package insert) for Albutrepenonacog alfa (Idelvion, CSL Behring) to confirm the approved indication, key warnings, and contraindications — this is currently a Blocking data gap
- Retrieve the complete mechanism of action from DrugBank (DB13884) to enable formal mechanistic analysis — currently a High severity data gap
- Redirect repurposing evaluation to Acquired Coagulation Factor Deficiency (Rank 7), which has the strongest mechanistic justification among all predicted candidates, as acquired Factor IX deficiency (e.g., amyloidosis-associated) represents a direct biological parallel to the approved Hemophilia B indication
- Before any further evaluation of the remaining candidates, conduct a mechanistic triage review — note that inherited thrombophilia (Rank 10) and thrombotic thrombocytopenic purpura (Rank 8) represent potentially contraindicated directions where Factor IX supplementation could theoretically worsen thrombotic risk
- Register Albutrepenonacog alfa with HSA Singapore if the primary Hemophilia B indication is commercially relevant, as the drug is currently not marketed in Singapore
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.